Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HTLV-1 Infection Clear all
Completed Phase 2 Interventional

Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)

NCT00001785
View directory record Official record
Conditions
HTLV-I Infection, Spinal Cord Disease, Tropical Spastic Paraparesis
Interventions
Recombinant human interferon beta-1a
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 3:56 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of Patients With HAM/TSP

NCT00001778
View directory record Official record
Conditions
HTLV-I Infection, Tropical Spastic Paraparesis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 3:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Anti-Tac for Treatment of Leukemia

NCT00001941
View directory record Official record
Conditions
HTLV-I Infection, T Cell Leukemia
Interventions
daclizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
10 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2012 · Synced Jul 22, 2026, 3:56 AM EDT
Completed Phase 4 Interventional

MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study

NCT03226119
View directory record Official record
Conditions
HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2, HTLV I Associated T Cell Leukemia Lymphoma, HTLV I Associated Myelopathies
Interventions
MP Diagnostics HTLV Blot 2.4
Diagnostic Test
Lead sponsor
MP Biomedicals, LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • San Antonio, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Jul 22, 2026, 3:56 AM EDT
Completed Phase 1 Interventional

Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

NCT00076843
View directory record Official record
Conditions
HTLV-1
Interventions
Hu MiK-Beta-1
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Jul 22, 2026, 3:56 AM EDT
Not listed No phase listed Observational

Evaluation of the MP Diagnostics HTLV Blot 2.4

NCT01467024
View directory record Official record
Conditions
HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2, HTLV I Associated T Cell Leukemia Lymphoma, HTLV I Associated Myelopathies
Interventions
CDPHL Algorithm
Other
Lead sponsor
MP Biomedicals, LLC
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Richmond, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Jul 22, 2026, 3:56 AM EDT
Completed Phase 2 Interventional Results available

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

NCT02631746
View directory record Official record
Conditions
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection, Lymphomatous Adult T-Cell Leukemia/Lymphoma, Smoldering Adult T-Cell Leukemia/Lymphoma
Interventions
Laboratory Biomarker Analysis, Nivolumab, Pharmacogenomic Study
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Baltimore, Maryland • Bethesda, Maryland • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Jul 22, 2026, 3:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

MRI Brain Studies in Patients With HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis

NCT00034723
View directory record Official record
Conditions
Tropical Spastic Paraparesis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 3:56 AM EDT
Terminated Phase 4 Interventional Results available

Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma

NCT00854581
View directory record Official record
Conditions
Lymphoma, Precancerous/Nonmalignant Condition
Interventions
PEG-interferon alfa-2b, Interferon alfa-2b, Valproic Acid, Zidovudine
Biological · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Jul 22, 2026, 3:56 AM EDT
Completed No phase listed Observational

Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer

NCT00001582
View directory record Official record
Conditions
T-cell Lymphoma, B-Cell Lymphoma, ATL, Myeloma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Jul 22, 2026, 3:56 AM EDT
Completed No phase listed Observational

Dual Algorithm Post Market Clinical Study

NCT03146013
View directory record Official record
Conditions
HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2, HTLV I Associated T Cell Leukemia Lymphoma, HTLV I Associated Myelopathies
Interventions
MP Diagnostics HTLV Blot 2.4
Diagnostic Test
Lead sponsor
MP Biomedicals, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Jul 22, 2026, 3:56 AM EDT
Terminated Phase 2 Interventional Results available

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

NCT03075553
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma, HTLV-1 Infection, NK-Cell Lymphoma, Unclassifiable, Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Mycosis Fungoides, Refractory Adult T-Cell Leukemia/Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Mycosis Fungoides, Refractory Nasal Type Extranodal NK/T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Laboratory Biomarker Analysis, Nivolumab
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Jul 22, 2026, 3:56 AM EDT
Completed Early Phase 1 Interventional

Raltegravir for HAM/TSP

NCT01867320
View directory record Official record
Conditions
HTLV-I Infection
Interventions
Raltegravir
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Jul 22, 2026, 3:56 AM EDT
Completed No phase listed Observational

Assessment of Patients With Multiple Sclerosis (MS)

NCT00001156
View directory record Official record
Conditions
Herpesviridae Infection, HTLV-I Infection, Multiple Sclerosis, Tropical Spastic Paraparesis, Vasculitis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 75 Years
Enrollment
1,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1976 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 3:56 AM EDT
Recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

NCT04301076
View directory record Official record
Conditions
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide, Lenalidomide, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Vincristine Sulfate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Atlanta, Georgia • City of Saint Peters, Missouri • Creve Coeur, Missouri + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 3:56 AM EDT